Soluble antibody/3H-double-stranded PM2 DNA (dsDNA) immune complexes were briefly opsonized with complement and then allowed to bind to human erythrocytes (via complement receptors). The cells were washed and subsequently a volume of autologous blood in a variety of media was added, and the release of the bound immune complexes from the erythrocytes was studied as a function of temperature and time. After 1-2 h, the majority of the bound immune complexes were not released into the serum during blood clotting at either 370C or room temperature, but there was a considerably greater release of the immune complexes into the plasma of blood that was anticoagulated with EDTA. Similar results were obtained using various conditions of opsonization and also using complexes that contained lower molecular weight dsDNA. Thus, the kinetics of release of these antibody/dsDNA immune complexes differed substantially from the kinetics of release of antibody/bovine serum albumin complexes that was reported by others. Studies using the solution phase Clq immune complex binding assay confirmed that in approximately half of the SLE samples that were positive for immune complexes, there was a significantly higher level of detectable immune complexes in plasma vs. serum. Freshly drawn erythrocytes from some SLE patients exhibiting this plasma/serum discrepancy had IgG antigen on their surface that was released by incubation in EDTA plasma. Thus, the higher levels of immune complexes observed in EDTA plasma vs. serum using the Clq assay may often reflect the existence of immune complexes circulating in vivo bound to erythrocytes.
Introduction
There is increasing evidence that indicates that erythrocytes (RBCs)' may play a key role in the normal removal from the 1. Abbreviations used in this paper: dsDNA, double-stranded DNA; NHSC, fresh normal human serum used as a complement source; GVB"2 buffer, gelatin-veronal buffer containing 0.5 mM MgCI2 and 0.15 mM CaC12; AHG, heat-aggregated human IgG; RBCs, human erythrocytes; I, C3b inactivator; C-DA, soluble, complement-opsonized DNA/anti-DNA immune complexes isolated by sucrose gradient ultracentrifugation; DA, soluble DNA/anti-DNA immune complexes; SLE, systemic lupus erythematosus. circulation of potentially pathogenic complement-fixing immune complexes (1) (2) (3) (4) (5) (6) (7) . It is now well established that the principal means by which RBCs bind such immune complexes is through their immune adherence receptors (CR,, specific for C3b and C4b) (6) (7) (8) (9) (10) (11) (12) (13) . Once bound to RBCs, the immune complexes can be removed from the RBC by passage through the liver (without RBC destruction) (7), or be released from the RBC through the action of serum factors such as C3b inactivator (I) (14, 15) . Several recent studies have demonstrated that in certain patients with immune complex-mediated diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis there is a reduction in the number of these receptors on their RBCs (2, 4, 5) , and we have presented evidence for a decrease in the complement-mediated binding of antibody/ double-stranded DNA (dsDNA) immune complexes to the RBCs of certain patients with these diseases (16) . It has been further suggested that immune complex-mediated tissue damage can result in these particular patients if the normal RBCmediated clearance mechanism for removal of immune complexes is impaired.
In view of the recognized importance of complementfixing antibody/dsDNA immune complexes in the pathogenesis of SLE (17) (18) (19) (20) (21) (22) (23) we have focused our studies on this system. While investigating the mechanism by which antibody/dsDNA immune complexes are released from normal vs. SLE RBCs, we were surprised to observe that significantly fewer immune complexes were released from normal or SLE RBCs in clotted blood compared with EDTA-chelated blood. This implies that there could be a discrepancy between apparent immune complex levels measured in plasma vs. serum, which could have a significant bearing on the detection of immune complexes in the circulation of patients with SLE (or other diseases). We report here the in vitro quantitation and analysis of this phenomenon, and furthermore, we also provide direct evidence that this observation is in fact relevant to a clinical immune complex assay (the Clq solution phase assay) in SLE patients.
Methods
Blood samples. Blood was collected from normal healthy volunteers or SLE patients (16) at the University of Virginia School of Medicine density gradients that were isokinetic for DNA (24) . The gradients were centrifuged for 105 min at 28,000 rpm at 40C (SW 28 rotor). The material that spun to the bottom of the gradient (2 -2005) was dissolved in borate saline (0.15 M NaCl, 0.03 M borate, pH 7.8) and frozen until use. This material (C-DA) was diluted in gelatin-veronal buffer containing 0.5 mM MgCl2 and 0.15 mM CaCl2 (GVB+2 buffer) (8) for use in the binding assays (see below). In a few cases, other SLE sera or plasma with high anti-dsDNA titers were used, and similar results to those reported for MA were obtained (see below).
In -1/2 of our experiments, antibody/3H-dsDNA complexes were prepared and opsonized with NHSC and bound to RBCs after our standard binding assay (9) . In this case the samples were not "purified" by the sucrose gradient ultracentrifugation procedure described above.
We will refer to these complexes as "whole serum" complexes, since these complexes remained in the serum milieu. Both Binding and release studies. In a typical experiment, multiple aliquots of 100 Ml each of a dilution of C-DA were incubated for 20 min at 37°C with 100 gl of a 25% suspension of freshly drawn and washed RBCs in glass centrifuge tubes. The samples were then centrifuged at 1,500 g for 3 min to pellet the RBCs, and the percentage of radiolabel bound to the cells was determined by counting 100 ul of the supernatant. The remaining supernatant was discarded, the cells were then gently washed with I ml of GVB`2 buffer, and the number of counts released in the entire wash was determined. Subsequently, I ml of the "releasing medium" (see below) was added to the RBC pellet that contained the bound antibody/3H-dsDNA immune complex, the sample was gently mixed, and then incubated for I h at 37°C or 2 h at room temperature (24°C). Subsequently, the sample was again centrifuged and the number of counts released after the final incubation was determined by counting 400 Ml of the supernatant. All determinations were run in duplicate.
When "whole serum" immune complexes were used, 100 M1 of the antibody/3H-dsDNA immune complex were incubated for 20 min at 37°C with 100 Ml of a 25% solution of RBCs and 50 ul of a fourfold dilution of NHSC. After the sample was centrifuged, 125 Ml of supernatant was counted to determine the percentage counts bound, and then the same release procedure described above for C-DA was used.
Preparation of "releasing media". All blood donors were bled twice on the day experiments were conducted. The first time they were bled, aliquots of their whole blood were stored in either Alsevier's solution (one part blood to two parts Alsevier's) or "lavender top" blood collection tubes (Vacutainer; Beckton-Dickinson & Co., Rutherford, NJ) (containing EDTA) or "blue top" blood collection tubes (containing sodium citrate) to prevent coagulation. A sample of blood from the Alsevier's solution was washed and used to supply RBCs for the initial binding assay (9) . When the release experiment was started ("2½ h after the first bleeding) the donor was bled again, and duplicate 1-ml aliquots of freshly drawn blood (not anticoagulated) were added immediately to the RBC pellets that contained the bound antibody/ 3H-dsDNA complexes. After mixing, the samples were allowed to clot at either 37°C for I h or -2 h at room temperature. Parallel studies were also conducted using 1-ml aliquots of the anticoagulated blood samples that were previously collected. Blood samples from different donors were never mixed; the pelleted RBCs from a given donor were only mixed with blood from the same individual. These experiments were specifically designed to closely simulate the typical procedure used in a hospital clinic for blood collection and processing. This is the reason whole blood was used as the "releasing medium." In a few experiments, fresh plasma or serum (not containing any RBCs) was used as a "releasing medium," and the same general trends were observed as for whole blood (see below).
Calculations and analysis. A number of other "releasing media" were also examined to determine their effect on the bound immune complexes. For purposes of clarity, we present in Table I Clq solution phase assay. We used the standard Clq assay (26) as we have previously reported (27) to measure immune complexes in plasma or serum samples from SLE patients. Plasmas were obtained after allowing the blood samples (anticoagulated with 0.01 M EDTA) to stand for I h at 370C. Standard curves using heat-aggregated human IgG (AHG) at multiple dilutions in phosphate-buffered saline (PBS) between 3 and 800 ug/ml were run each day. Typically, a concentration of 800 Ag/ml gave 60% '25I-Clq binding, 50 jg/ml gave 21% binding, and 12 Ag/ml gave 15% binding. The lower limit of sensitivity in the assay ranged between 5- On the other hand, "whole serum" immune complexes were considerably more labile, because in addition to the release of some bound counts during the wash (typically 30%), >50% of the remaining bound counts were released during incubation in blood samples that were anticoagulated with either EDTA, citrate, or Alsevier's solution (Fig. 2) . It should also be noted that during blood clotting at 370C, only -25% of these complexes were released, and if the blood was allowed to clot at room temperature (240C) then the amount released averaged <10% (Fig. 2) .
C-DA that was prepared with sonicated dsDNA lead to similar trends (Fig. 3) . The complexes were usually released with high efficiency in blood anticoagulated with EDTA, but if the blood was allowed to clot during the incubation there was less release at 370C, and even a smaller fraction was released during clotting at room temperature. (Fig. 3) .
The differences between samples allowed to clot vs. anticoagulated samples with respect to the amount of immune complex released from the RBCs were also affected by kinetic considerations. In fact, the percentage of immune complex released in the anticoagulated samples at 240C depended upon the amount of time the samples were allowed to stand before they were centrifuged (Table II) DTA was added to the GVB+2 "releasing medium" to a final concentration of -0.01 M, and the degree of release of the bound immune complexes was not significantly different from that seen in GVB+2 buffer alone. Alsevier's solution alone (not containing any blood) gave results similar to those observed for GVB+2 buffer.
We have also investigated whether the antibody/DNA immune complexes could be released more rapidly in the absence of the additional RBCs in the "releasing media." When a release study was conducted at 37°C for 1 h by adding 1 ml of fresh normal human serum alone to C-DA bound to RBCs, 40% of the counts were released, and 49% were released when 1 ml of fresh plasma alone (containing EDTA) was used to effect release. The companion experiment with 1 ml of whole blood gave 16% release (sample allowed to clot) and 75% release in whole blood samples that were anticoagulated with EDTA. In another experiment, we used either fresh normal human serum alone or heat inactivated normal human serum as the "releasing media" for bound, "whole serum" immune complexes. After 1 h at 37°C, 52% of the bound Preliminary characterization of the released immune complexes. Antibody/3H-dsDNA immune complexes that were released from the clotted RBCs could be precipitated (.85%) in 50% saturated ammonium sulfate, and in addition still had S values of at least 200S because they were pelleted when subjected to the sucrose gradient ultracentrifugation procedure described above for the initial preparation of C-DA. However to bind complement-fixing antibody/dsDNA immune complexes (16) . Therefore, we have also examined the blood of a few selected SLE patients (some with "normal" RBCs patients we examined had significant levels of immune complexes (>10 gg/ml equivalents of AHG) in either plasma or serum, and the results for these individuals are seen in Table   III . In about half of these positive samples we detected a significantly higher immune complex concentration in the plasma samples (group I of Table III (Fig. 1) .
The comparable study for the SLE patients gave a percentage release of 17.3±6.0 SD.
are not released into the serum during blood clotting. This lack of release is even more pronounced at room temperature than at 370C. The generality of these observations is first demonstrated by the fact that they are obtained for immune complexes that are opsonized under different conditions (Figs.  1 and 2) . Secondly, similar results are seen for immune complexes containing lower molecular weight dsDNA (Fig. 3) . Finally, the low degree of release during clotting is demonstrable for the blood of both normal individuals and SLE patients, whose RBCs had reduced immune complex binding capacity (Fig. 4) . Although it has been suggested that in studies directed It might be expected, based on in vitro studies with bovine serum albumin (BSA)/anti-BSA immune complexes (10) , that immune complexes would be rapidly released from RBCs in vivo via interaction with I (10, 14, 15) . However, we have noted that this release reaction is not nearly so rapid for the antibody/3H-PM2 dsDNA system in vitro (see Results, "Investigation of possible mechanisms"), and we have no information on how efficiently the process would operate on different immune complexes in vivo. We also emphasize that dsDNA/IgG anti-dsDNA immune complexes form moderately large, soluble immune complexes that fix complement quite efficiently, and they generally do not show any evidence for cross linking (30, 47) . The physical chemistry of these immune complexes is quite different from that observed for immune complexes containing globular protein antigens. This may provide an explanation for the significant differences in the release kinetics between the dsDNA/human anti-dsDNA system we have examined and those reported for the BSA/guinea pig anti-BSA system (10, 14, 15) .
The clearance mechanism reported by Cornacoff et al. (7) would also tend to reduce the level of RBC-bound immune 
